Loading
Gastrointestinal Motility and Disorders · Journal article
International Journal of Endocrinology · August 6, 2026
Reinforces what was already believed, rather than introducing something new.
This cross-sectional study found elevated fasting serum gastrin-17 levels in patients with GERD combined with chronic obstructive pulmonary disease or asthma, with levels correlating strongly with body mass index (r = +0.64, p < 0.001) and waist circumference (r = +0.59, p < 0.001). Elevated gastrin-17 was associated with more severe GERD manifestations including increased nocturnal reflux episodes and erosive mucosal lesions, and negatively correlated with lung function (FEV1, r = –0.52, p < 0.01). The data support obesity as a significant driver of hypergastrinemia in the setting of GERD and respiratory comorbidity, though causality cannot be inferred from this design.
Cross-sectional observational study. 102 patients with COPD (n=42) or bronchial asthma (n=60) with GERD, and 25 outpatients with varying degrees of obesity; setting not specified.. n = 127.
GERD + COPD group had highest gastrin-17 at 19.6 ± 3.2 pg/mL; GERD + BA group at 17.3 ± 2.9 pg/mL Strong positive correlation between body mass index and gastrin-17 (r = +0.64; p < 0.001) Positive association between waist circumference and gastrin-17 (r = +0.59; p < 0.001)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that elevated gastrin-17 in obese patients with GERD and concurrent respiratory disease (COPD or asthma) is associated with more severe reflux manifestations, nocturnal symptoms, and erosive lesions, potentially necessitating more aggressive antisecretory therapy. The correlation with obesity severity suggests weight management as an adjunctive target in this population.
Observational study demonstrating associations between gastrin-17 levels and GERD severity in comorbid disease, with moderate sample size and statistically significant correlations, but lacking a control arm and mechanistic intervention.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that elevated gastrin-17 in obese patients with GERD and concurrent respiratory disease (COPD or asthma) is associated with more severe reflux manifestations, nocturnal symptoms, and erosive lesions, potentially necessitating more aggressive antisecretory therapy. The correlation with obesity severity suggests weight management as an adjunctive target in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Modern clinical medicine regards gastroesophageal reflux disease (GERD), chronic obstructive pulmonary disease (COPD), bronchial asthma (BA), and obesity as interconnected pathological states that form a unified metabolic-inflammatory cascade. Gastrin-17, a hormone of the gastric antrum, is one of the key regulators of acid secretion. The purpose of the study was to evaluate gastrin-17 levels in patients with GERD combined with COPD or BA against a background of obesity, and to assess their correlation with clinical and anthropometric parameters. Materials and methods. The study involved 102 patients diagnosed with COPD (n = 42) and BA (n = 60), as well as 25 outpatients with varying degrees of obesity. Fasting serum gastrin-17 levels were determined using the enzyme-linked immunosorbent assay. Results. The highest gastrin-17 content was observed in group 1 (GERD + COPD) at 19.6 ± 3.2 pg/mL and group 2 (GERD + BA) at 17.3 ± 2.9 pg/mL. In patients of groups 3 (COPD) and 4 (BA), gastrin-17 levels were near the upper limit of the normal range, while in group 5 (obesity) they were intermediate, with a tendency to increase depending on body mass index (from 13.2 ± 2.6 pg/ml to 20.2 ± 3.5 pg/ml). A strong positive correlation was found between body mass index and gastrin-17 content (r = +0.64; p < 0.001), as well as a positive association with waist circumference (r = +0.59; p < 0.001). An increase in gastrin-17 levels was recorded alongside the progression of obesity severity. Patients with elevated gastrin-17 exhibited clinical manifestations of GERD, more frequent nocturnal reflux episodes (r = +0.61; p < 0.001), erosive mucosal lesions, and decreased efficacy of antisecretory therapy. In patients with BA, typical esophageal symptoms of reflux during the night were significantly more frequent (odds ratio 1.3–1.5; p < 0.05), showing a distinct causal sequence: reflux → bronchospasm → asthma attack. Conversely, patients with COPD more frequently presented with atypical gastrointestinal symptoms, including chronic cough without heartburn, belching, flatulence, throat irritation, and hoarseness. A negative correlation was found between FEV1 and gastrin-17 levels (r = –0.52; p < 0.01). Conclusions. In patients with GERD and comorbid respiratory diseases associated with obesity, there is an elevation in gastrin-17. This parameter correlates positively with body mass index, highlighting the significant role of obesity in the development of hypergastrinemia. Elevated gastrin-17 content is associated with a more severe course of GERD, characterized by more frequent nocturnal symptoms and erosive mucosal lesions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.